ProKidney Corp (PROK)
NASDAQ (CM) NASDAQ (CM) Primary 
XMEX Summary
PROK Chart
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
ProKidney Corp Dividends
ProKidney Corp Earnings
| 8 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 17 Mar 2025 Date | | - Cons. EPS | - EPS |
| 10 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 17 Mar 2025 Date | | - Cons. EPS | - EPS |
| 10 Nov 2024 Date | | - Cons. EPS | - EPS |
ProKidney Corp (PROK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has ProKidney Corp ever had a stock split?
ProKidney Corp Profile
| Biotechnology Industry | Healthcare Sector | Bruce Culleton CEO | NASDAQ (CM) Exchange | 74291D104 Cusip |
| US Country | 204 Employees | - Last Dividend | - Last Split | 12 Jul 2022 IPO Date |
Overview
ProKidney Corp. is a pioneering entity in the biotechnology sector, focusing its efforts on the advancement of cell therapy platforms aimed at the amelioration of chronic kidney diseases. With its inception in 2015, the company has dedicated itself to developing innovative therapeutic solutions from its headquarters in Winston-Salem, North Carolina, USA. The primary mission of ProKidney Corp. is to introduce groundbreaking treatments that offer hope and improved outcomes for patients suffering from various kidney ailments, leveraging the vast potential of cell therapy technologies.
Products and Services
- Renal Autologous Cell Therapy (REACT):
This flagship product embodies the core of ProKidney Corp.'s innovative approach towards tackling chronic kidney diseases. REACT is a cutting-edge therapeutic modality based on the use of autologous homologous cell admixtures. This treatment has successfully completed its Phase I clinical trial, targeting patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Building upon this initial success, REACT has progressed to Phase III and Phase II clinical trials for addressing moderate to severe diabetic kidney disease, highlighting its potential as a transformative solution for a widespread and impactful health challenge.
Contact Information
